Market Cap | 65.18M | P/E | - | EPS this Y | 3.00% | Ern Qtrly Grth | - |
Income | -58.21M | Forward P/E | -1.27 | EPS next Y | -31.00% | 50D Avg Chg | -12.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
Dividend | N/A | Price/Book | 0.51 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | 1.70 | Quick Ratio | 11.50 | Shares Outstanding | 55.37M | 52W Low Chg | 32.00% |
Insider Own | 11.51% | ROA | -34.67% | Shares Float | 31.30M | Beta | 1.19 |
Inst Own | 71.69% | ROE | -58.75% | Shares Shorted/Prior | 1.05M/1.32M | Price | 1.77 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 23,227 | Target Price | 12.33 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 46,141 | Change | 0.57% |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Maxim Group | Buy | Aug 6, 24 |
HC Wainwright & Co. | Buy | Aug 6, 24 |
BTIG | Buy | Jul 17, 24 |
Craig-Hallum | Buy | Jun 4, 24 |
HC Wainwright & Co. | Buy | May 22, 24 |
HC Wainwright & Co. | Buy | May 16, 24 |
JMP Securities | Market Outperform | Apr 19, 24 |
JMP Securities | Market Outperform | Apr 18, 24 |
JonesTrading | Buy | Apr 18, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ROBERTS BRIAN KENNETH | Chief Medical Office.. Chief Medical Officer | Jul 03 | Buy | 1.8999 | 5,000 | 9,500 | 27,552 | 07/06/23 |
ROBERTS BRIAN KENNETH | Sr VP, Clinic Develo.. Sr VP, Clinic Development | May 04 | Buy | 3.80 | 21,052 | 79,998 | 21,052 | 05/06/22 |
Labrucherie Gil M | Director Director | May 04 | Buy | 3.80 | 52,631 | 199,998 | 52,631 | 05/06/22 |
Hogenhuis Wladimir | Director Director | Oct 15 | Buy | 5.15 | 32,693 | 168,369 | 32,693 | 05/06/22 |